Ben Fidler
Lead Editor | @BentheFidlerBen is a lead editor for BioPharma Dive. He is a veteran business journalist with more than 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
935 articles by Ben Fidler
-
Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
Oct. 12, 2026 -
The top biopharma conferences in 2027
Oct. 6, 2026 -
Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
Oct. 5, 2026 -
Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
Oct. 5, 2026 -
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
Sept. 30, 2026 -
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
Sept. 29, 2026 -
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
Sept. 28, 2026 -
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Sept. 25, 2026 -
Lilly’s latest China drug deal; Immunovant’s setback in lupus
Sept. 24, 2026 -
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Sept. 22, 2026 -
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
Sept. 21, 2026 -
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
Sept. 18, 2026 -
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
Sept. 15, 2026 -
Scholar Rock SMA drug approved by FDA
Sept. 14, 2026 -
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Sept. 5, 2026 -
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
Aug. 31, 2026 -
FDA extends review of Capricor cell therapy; Pain drug startup to go public
Aug. 24, 2026 -
Cancer vaccine win restores Wall Street’s faith in Moderna
Aug. 20, 2026 -
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
Aug. 6, 2026 -
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
Aug. 5, 2026 -
Alnylam plunges as earnings deliver ‘one-two punch’
July 30, 2026 -
Capricor Duchenne cell therapy voted down by FDA panel
July 29, 2026 -
FDA scientists question Capricor data; Legend CEO steps down
July 27, 2026 -
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
July 27, 2026 -
Scribe secures $129M in a rare gene editing IPO
July 23, 2026